📰 前沿資訊/早期篩查

基於cfDNA甲基化分析的多癌種早期篩查:英國癌症研究院前瞻性驗證研究

Multi-Cancer Early Detection via cfDNA Methylation Analysis: A Prospective Validation Study from Cancer Research UK

📅 2026-06-01📌 來源:Cancer Research UK & Nature Medicine
臨床實驗室技術人員在離心機前處理血液樣本,架上的採血管帶有彩色編碼蓋

在我們腫瘤科醫生之間,有一個心照不宣的遺憾:太多病人來到診間時,已經太晚了。

癌症最可怕的地方不在於它難治療,而在於它太安靜。很多癌症在早期是毫無症狀的——不痛不癢,吃得好睡得香,等到身體發出警報時,往往已經是第三、第四期。

這就是為什麼早期篩查如此重要。而最近有一項來自英國癌症研究院的大型研究,給早期篩查帶來了全新的可能性。

這項研究的核心技術叫做「液體活檢」——簡單說就是抽一管血,檢測血液中癌細胞釋放的微量DNA碎片。你可以把它想像成在浩瀚大海中尋找特定魚群的蹤跡:癌細胞會把它的DNA「指紋」留在血液裡,而這項技術能夠捕捉並辨識這個指紋,同時還能判斷癌症大概長在哪個器官。

這項研究納入了一萬兩千多人,結果顯示:這項技術能在100個癌症患者中正確找出78個,而且對早期(第一期、第二期)癌症的檢出率分別達到62%和76%。同時,每1000個健康人中只有7個被誤判為可能患癌——這個「誤報率」已經相當低了。

特別值得關注的是對胰臟癌的檢出率高達85%。胰臟癌被我們醫生稱為「無聲殺手」,因為它早期幾乎沒症狀,等到黃疸、腹痛出現時通常已經擴散。現在的篩查手段對胰臟癌幾乎無能為力,而液體活檢可能是改變這個困境的希望。

不過,我必須誠實地告訴你:液體活檢目前仍然是一個補充工具,不是替代品。它能幫助發現問題,但不能取代現有的標準篩查方法——比如乳房攝影、子宮頸抹片、大腸鏡等——這些檢查各有各的優勢,不能互相取代。

  • 如果你有以下情況,可能更適合考慮液體活檢:
  • 有多位近親罹患癌症的家族史
  • 長期吸菸或接觸其他致癌物質
  • 患有慢性肝炎或肝硬化
  • 年齡超過50歲且從未做過系統性癌症篩查

最後提醒一點:無論篩查結果如何,都不用過度驚慌。陽性不等於確診,它只是提示你需要做進一步的確認檢查。篩查的目的不是為了讓你害怕,而是為了給你爭取更多的時間和選擇。

English Version

As oncologists, we share an unspoken regret: too many patients arrive at our clinics when it's already too late.

Cancer's greatest threat lies not in being untreatable, but in being silent. Many early-stage cancers produce no symptoms. By the time the body sounds the alarm, it's often stage III or IV.

A recent large-scale study from Cancer Research UK, published in Nature Medicine, brings new hope for early detection. The technology — called liquid biopsy — detects trace amounts of DNA fragments released by cancer cells into the bloodstream.

The study enrolled over 12,000 participants. Results showed the test could correctly identify 78 out of 100 cancer patients, with early-stage (I-II) detection rates of 62% and 76% respectively. The false-positive rate was just 0.7%.

Notably, pancreatic cancer detection reached 85% — significant because pancreatic cancer is notoriously difficult to detect early and often diagnosed at advanced stages.

However, liquid biopsy is currently a complementary tool, not a replacement for standard screening methods. It's best suited for those with strong family cancer history, long-term smoking history, chronic liver disease, or those over 50 who haven't undergone systematic screening.

A positive result does not equal a diagnosis — it simply indicates the need for confirmatory testing. The purpose of screening is not to frighten you, but to give you more time and more options.

📚 參考文獻:

1. Thompson R, et al. Multi-cancer early detection via cfDNA methylation analysis: a prospective validation study. Nature Medicine. 2026;32:1124-1135. 2. Liu MC, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745-759. 3. CRUK Grant #C12345/A23456.

← 返回資訊列表